The vitamin, folic acid, has become a useful ligand for targeted cancer therapies because it
binds to a tumor-associated antigen known as the folate receptor (FR). By linking folic acid to …

The cell surface receptor for the vitamin folic acid (termed the folate receptor), is often
elevated in cancers of the ovary, kidney, lung, mammary gland, brain, endometrium, and …

We previously exploited the frequent overexpression of folate receptors on cancer cells to
decorate malignant cell surfaces selectively with folate‐hapten conjugates. In antihapten …

A variety of human cancers overexpress a cell surface receptor with high affinity for the
vitamin, folic acid (K d~ 10–10 M). Covalent attachment of therapeutic agents to folic acid …

1.1. General Strategies in the Design of Tumor Targeted Therapeutics. Today's quest for
developing tumor-targeted therapies has naturally followed two nonoverlapping strategies …

The membrane-bound folate receptor (FR) is overexpressed on a wide range of human
cancers, such as those originating in ovary, lung, breast, endometrium, kidney and brain …

Cancer therapies that exploit targeting ligands to deliver attached cytotoxic drugs selectively
to malignant cells are currently receiving significant attention. While antibody-targeted drugs …

The vitamin folic acid (FA) enters cells either through a carrier protein, termed the reduced
folate carrier, or via receptor-mediated endocytosis facilitated by the folate receptor (FR) …

The folate receptor (FR) is a confirmed tumor-associated antigen that binds folate and folate–
drug conjugates with very high affinity and shuttles these bound molecules inside cells via …

The folate receptor is a highly selective tumor marker overexpressed in greater than 90% of
ovarian carcinomas. Two general strategies have been developed for the targeted delivery …